Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: Exploratory analysis from the CASCADE trial

Journal of Cardiothoracic Surgery

Volumn 8, Issue 1, 2013, Pages

  Jerzewski, Katie ^a,d   Ruel, Marc ^b   Voisine, Pierre ^c   Le May, Michel R ^b   Kulik, Alexander ^a,d  

^a BOCA RATON REGIONAL HOSPITAL   (United States)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cholesterol; Coronary artery bypass graft surgery; Graft patency; HDL; Vein graft disease

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN; TICLOPIDINE;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGIOGRAPHY; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; GRAFT OCCLUSION, VASCULAR; HUMAN; HYPERPLASIA; INTIMA; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAPHENOUS VEIN; TRANSPLANTATION;

AGED; ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE PERIOD; RISK ASSESSMENT; SAPHENOUS VEIN; TICLOPIDINE; TUNICA INTIMA;

EID: 84880027014     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-8-172     Document Type: Article

References (21)

1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circ 1998, 97:916-931.
2. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med 1997, 336:153-162.
3. Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg 2011, 92:1284-1290. discussion 1290-1281, 10.1016/j.athoracsur.2011.04.107, 21958773.
4. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM, et al. ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circ 2011, 2011(124):e652-e735.
5. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310. 10.1056/NEJMoa064278, 17898099.
6. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl 2011, 12:267-270. 10.1016/S1567-5688(11)70885-6, 22152280.
7. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
8. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122. 10.1056/NEJMoa0907569, 19915217.
9. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197. 10.1016/j.jacc.2004.10.031, 15653014.
10. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Predicting coronary heart disease in middle-aged and older persons. The Framington study. JAMA 1977, 238:497-499. 10.1001/jama.1977.03280060041018, 577575.
11. Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 2011, 97:1943-1950. 10.1136/hrt.2011.225466, 3210465, 21665885.
12. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circ 2000, 102:III90-III94.
13. Sabik JF, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circ 2006, 114:I454-I460.
14. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR, Lopid Coronary Angiography Trial (LOCAT) Study Group Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circ 1997, 96:2137-2143. Lopid Coronary Angiography Trial (LOCAT) Study Group.
15. Kulik A, Le May M, Wells GA, Mesana TG, Ruel M. The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med 2005, 6:15. 10.1186/1468-6708-6-15, 1282584, 16219100.
16. Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circ 2010, 122:2680-2687.
17. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508. 10.1001/jama.297.5.499, 17284700.
18. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122. 10.1056/NEJMoa0706628, 17984165.
19. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853. 10.1016/S0140-6736(96)91343-4, 8622389.
20. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001, 357:905-910.
21. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006, 97:27C-31C. 10.1016/j.amjcard.2005.12.007, 16581325.